SaaS entity
Crinetics Pharmaceuticals is most often covered alongside Advanced Micro Devices, which appears in 1 of these 2 stories. They are better corroborated than the beat average, carrying 9.5 original sources each against 3.1 for the same window. The 135-day window averages about 0.1 stories each week.
Last mentioned: Jul 31, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Crinetics Pharmaceuticals is most often covered alongside Advanced Micro Devices, which appears in 1 of these 2 stories. They are better corroborated than the beat average, carrying 9.5 original sources each against 3.1 for the same window. The 135-day window averages about 0.1 stories each week. Their average consequence score of 7 runs above the beat's 6.5 for that window. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 SaaS stories that mention Crinetics Pharmaceuticals, published between February 27, 2026 and July 11, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 875 SaaS stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Crinetics Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
The 1.2% Nasdaq drop, driven by 6-10% plunges in AMD, Intel, and Micron, reflects growing fears that massive AI infrastructure investments may not yield proportionate returns. For SaaS and cloud providers that have hitched growth narratives to AI-driven demand, the sell-off raises urgent questions about the sustainability of enterprise software spending.
The Q4 2025 earnings cycle highlights a significant shift toward recurring revenue and high-performance computing (HPC) across the hardware and biotech sectors. Arlo Technologies achieved a landmark Rule of 40 score, while TeraWulf and Aeva Technologies signaled deeper integrations into the AI infrastructure ecosystem.
Crinetics Pharmaceuticals is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
